We wish everyone a Happy New Year from 84 innovative Chinese enterprises! As we stand at this intersection of time, reflecting on our past and looking toward the future, we recognize that the past year has been a journey through cycles. Chinese innovative enterprises have faced the chill of funding droughts and witnessed the warmth of favorable policies. We’ve navigated technical bottlenecks and celebrated breakthroughs in overcoming challenges.
These ups and downs and our perseverance make our New Year greetings a heartfelt promise, born from trials and tribulations. This is the essence of the “Chinese Innovative Enterprises New Year Messages” initiative launched by our organization. We understand that the industry’s vitality doesn’t depend on a single voice but rather shines through the multitude of individual contributions.
From dedicated researchers in laboratories to supply chain practitioners hustling for innovative products, and long-term investors bolstering the industry with capital—each voice reflects the true measure of our history. Today, as the voices of numerous innovative enterprises converge, we see not just grand narratives but a vivid portrait of industry spirit: some choose to believe in long-termism in tough times, while others define the “next decade” in uncharted areas. These voices serve as encouragement for the present and echoes for the future.
As the new lunar year unfolds, we invite you to receive these brilliant insights from our fellow innovators—each message is equally precious, regardless of the order in which they arrived.
Dr. Du Jun, Vice President of Beijing Qingsi Biotechnology Co., Ltd.
As the New Year arrives, I wish all colleagues and partners close ties like gene sequences, resilient in the wave of synthetic biology, and thriving together. Over the past year, our industry has demonstrated resilience amidst challenges, uniting in collaboration. In the new year, I look forward to working with more colleagues to accelerate the entire life sciences journey from R&D to industrial implementation through “AI + Molecular Manufacturing.” As we look to 2026, may the Chinese innovation ecosystem rise like a spiraled DNA, persistently breaking through technological boundaries and crossing industrial cycles. Let us anchor our efforts in the “gene factory,” writing a new chapter from “reading, modifying, writing” to “creating all things,” empowering a healthy China and a green future!
Chen Zhengju, CTO of Bait Biological
In 2025, the in-body CAR pathway grew amidst breakthroughs. With our LINCMECAR® technology and tpLNP delivery system, we are speeding up clinical translation. In 2026, may the entire industry unite, breaking through barriers with resilience, enabling more precise therapies to benefit countless patients! May spring accompany us always, and may our new journey be smooth, as we, in the medical field, fulfill our mission with sincerity and warm lives through innovation!
Zhou Lu, Founder of Shentuo Bio
2026 will be a year of accelerated development in the CGT field, with in-body CAR-T therapies blooming in various applications. The use of in-body CAR-T will expand from hematological malignancies to autoimmune diseases, solid tumors, and even inflammatory metabolic areas. Various modalities and delivery methods will emerge, and innovations like lentivirus + LNP and systemic + local delivery clinical designs will appear. The upstream and downstream industrial chains, including CMC processes, such as the serum-free suspension process developed by Shentuo, will further reduce production costs and enhance patient accessibility. Rare diseases and orphan drugs for adults will accelerate clinical advancements, and once safety is confirmed in adults, orphan drugs for children will significantly accelerate in this field. In 2026, we will see more clinical data disclosures, laying a solid foundation for multiple BD, financing, and mergers and acquisitions.
Liu Bing, Founder of Mingshi Brain-Machine Interface
In 2026, brain-machine interfaces will cross the threshold of “technical breakthroughs,” diving into “clinical deep waters.” We anticipate more precise closed-loop interventions to solve challenges in vision, epilepsy, and depression, as well as smarter and lighter adaptive implant devices that elevate brain-machine interfaces from mere “therapeutic tools” to true “partners” in human potential. Our journey is long, but respect and our original intentions guide our direction. Together, let us use clinical value as our beacon, focusing on patient needs, and bridge the final mile from the lab to the bedside.
Xu Jin, General Manager of Beijing Tianzhihang Medical Technology Co., Ltd.
As the New Year approaches, I extend sincere blessings to all fellow travelers on the road of medical innovation! May the new year bring prosperity and happiness to everyone! I hope that the coming year sees the industry basking in the spring sunshine, bringing forth a refreshing new environment. The future of medical robots lies in the synergy of technology and humanity, where each breakthrough carries the hope for better lives. Tianzhihang will continue to empower doctors and assist patients in their recovery, ensuring that every technical advancement translates into accessible benefits for patients. The journey is long, but the future is promising; let us stride into the vast future of smart healthcare together!
Zhang Yan, Co-founder and Senior Vice President of Megar Technology
As the New Year arrives, may the industry gallop like a steed, crossing cycles and chasms. Over the past year, we’ve often stated, “Use automation to free scientists’ hands and arm their brains with artificial intelligence.” This is not just a slogan but a reality we see every day in laboratories and production lines—scientists liberated from repetitive tasks and AI beginning to reason independently, quietly changing the pace of innovation. Our all-in commitment to AI aims not only to help clients become “super companies” but also to drive the entire industry from “catching up” to “leading.” In the AI era, everyone can become a “super individual,” and every enterprise can leap forward. Megar aims to be a platform-driven enabler, standing shoulder to shoulder with partners, using AI to drive science and automation to empower discoveries. In 2026, let us continue our journey together, leaving a clear and strong “hoofbeat” of Chinese innovation on the world’s track.
Luo Xiaozhou, Researcher at the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Founder & CTO of Senrise Biotechnology (Shenzhen) Co., Ltd.
To colleagues—let us thrive and prosper together!
Fear not the storms and rain! Chinese biotechnology never shies away from long and difficult paths. May we carry the mission of “creating knowledge through manufacture, and opening sources for practical use,” and forge ahead.
Li Chao, Deputy General Manager of Suzhou Womei Biotechnology Co., Ltd., Executive Dean of East China University of Science and Technology Qingdao Innovation Research Institute
With the arrival of the New Year, everything is renewed. On behalf of Womei Biotechnology, I extend sincere blessings to all industry partners and colleagues! We remain focused on upstream biomanufacturing, committed to building an integrated service platform of “product-process-engineering-equipment,” helping the biomanufacturing industry reduce costs, improve efficiency, and accelerate innovation transformation. Looking to the future, we firmly believe biomanufacturing will evolve towards higher efficiency, greater intelligence, and stronger collaboration. Womei will continue to delve into upstream technology and engineering capabilities, working hand in hand with the industry chain to break through key segments, jointly pushing the Chinese biomanufacturing ecosystem towards intensiveness and intelligence. May the new year foster resilience in the industry, and may innovation advance continuously!
Yu Ruijin, Chairman of Yipin Group
As the Year of the Horse arrives, may everything commence anew. On this occasion of the 2026 Lunar New Year, I, on behalf of all Yipin employees, extend my most sincere greetings to all innovators and colleagues in the medical device industry! May everyone achieve success in the new year and lead the way in research and development!
Zhang Jinbao, President of Miaoshun Biotechnology
As we usher in the New Year, we celebrate every step of China’s biopharmaceutical innovation. May the spark of innovation in China’s biopharmaceutical industry grow stronger through trials, ultimately becoming a raging fire. In the future, Miaoshun will continue to leverage high-quality original cells as the foundation for innovation, high-efficiency cryopreservation solutions as guardians of life, and precise magnetic beads to empower research purification, accelerating the transformation of achievements and breakthroughs in the industry alongside China’s biopharmaceutical professionals.
Hu Meirong, General Manager of Yilian Health
In 2025, we laid the foundation for our “Eight Dimensions Integration” full-chain service in Chengdu Wenjiang Digital Medical Industrial Park, weaving a network covering system solutions, license applications, physician groups, pharmaceutical supply chains, digital marketing for doctors, and cloud clinic joint operations, ensuring that every step in digital healthcare is solid and powerful. In 2026, let us continue to be the “water bearers” of the industry, using the Chengdu Wenjiang industrial park as a hub to strengthen the national service network, allowing more resident enterprises to share the triadic dividends of “policies + resources + operations.” May the entire industry unite to break through challenges and move forward toward new horizons, allowing quality healthcare to transcend mountains and seas, reaching every life!
Liu Hao, CTO of Tianmu Technology
In 2025, we focused on AI protein design, using the AIACCLBIO® large model as our core, linked with an automated experimental platform, continuously breaking through the bottlenecks of molecular design accuracy and conversion efficiency, gradually transforming technological advantages into industrial productivity. Looking to 2026, may we walk alongside industry colleagues, using technological innovation as our sail and practical action as our oar to drive AI protein design technology across the divide between R&D and industry, injecting new momentum into biopharmaceuticals, functional foods, and biomaterials. Let us not disappoint the industry’s expectations or the mission of the times.
Tang Yongzhai, Chairman of Tekang Pharmaceuticals
As the new year begins, we reflect on 2025, where the special medical food industry saw breakthroughs driven by policies and clinical needs, surpassing a domestic production rate of 87%. Innovations in liquid dosage forms and precise nutritional interventions became key to breaking through. Tekang Pharmaceuticals has focused on nutrition formulas for specific diseases, leveraging “local research and development + quality control throughout the chain” to transition nutrition treatment for chronic diseases like cancer, kidney disease, and Alzheimer’s from hospitals to homes, allowing scientific nutrition to benefit millions of patients. Looking to 2026, the industry will accelerate towards a new stage of “precision + intelligence.” We hope to work with academia, industry, and healthcare to unlock health secrets through technology, providing customized nutrition and AI-powered health management, breaking through boundaries in special medical food dosage forms and scenarios, and building an ecological loop of “products + services + data.” May the light of the new year illuminate every path of innovation, making nutritional therapy an indispensable cornerstone of health in China!
Chen Feng, CEO of Boliang Capital
At the beginning of the new year, Boliang Capital, along with all its colleagues, extends sincere blessings to our partners in the healthcare sector! May the new year see a surge of innovation in the industry, fostering win-win cooperation, and embarking on a new journey of high-quality development together. Looking forward to 2026, global pharmaceutical innovation and cross-border cooperation will accelerate. Leveraging the industrial foundation of Kelinlikang and my over 20 years of experience in multinational pharmaceutical management and BD, we will continue to delve into biopharmaceuticals and high-end equipment, connecting with over 10,000 pharmaceutical companies, biotech firms, and investment networks globally, providing comprehensive support for enterprises in licensing, clinical strategies, and financing, facilitating stable international expansion of Chinese innovation and precise localization of global resources. Let us work together with industry peers to propel the co-construction of the healthcare ecosystem and embrace a new chapter of industry integration and breakthroughs!
Wang Wenming, Global Market Director of Haier Bio
Looking to the future, we are at a critical juncture of intelligent and personalized transformations in global biomedicine. AI + automation is reconstructing research laboratory scenarios, and green refrigeration technology is aiding global carbon neutrality—competition in the next decade will unfold at the intersection of technical depth and ecological breadth. Haier Bio’s mission in overseas markets is not just to export Chinese products but to co-create and build with global partners. We aim to be practical builders crossing the “valley of death”: enhancing medical infrastructure in emerging markets and assisting developed markets in upgrading research and medical services intelligently; we also aspire to be dreamers who dare to define the future: actively exploring global brand creation, becoming the top share in key countries like the UK, firmly maintaining original technology, continually leading the industry’s technological development route, and participating in the formulation of international standards for cell storage.
In 2026, let us embrace global innovative resources with a more open posture and climb into uncharted technical territories with more determined steps. The spring breeze has arrived, and everything is renewed. May we, on this most meaningful path of safeguarding life, address current challenges while gazing at the stars to create infinite possibilities. The future is ours!
Dr. Hao Yuyou, Founder and Chairman of Mansen Biotechnology
The New Year brings a fresh chapter. Mansen Biotechnology, with its dedication to craftsmanship, witnesses every leap in China’s biopharmaceutical innovation. May the flame of innovation in China’s biopharmaceutical industry burn brighter through the tempering of cycles, ultimately creating a sweeping force. In the future, Mansen will continue to focus on high-quality raw cells as the foundation for innovation, high-efficiency cryopreservation solutions as a safeguard for life, and precise magnetic beads to empower research purification, accelerating result transformation, and breaking through the industry alongside the Chinese biopharmaceutical community.
Hu Meirong, General Manager of Yilian Health
In 2025, we laid the foundation for our “Eight Dimensions Integration” full-chain service in Chengdu Wenjiang Digital Medical Industrial Park, weaving a network covering system solutions, license applications, physician groups, pharmaceutical supply chains, digital marketing for doctors, and cloud clinic joint operations, ensuring that every step in digital healthcare is solid and powerful. In 2026, let us continue to be the “water bearers” of the industry, using the Chengdu Wenjiang industrial park as a hub to strengthen the national service network, allowing more resident enterprises to share the triadic dividends of “policies + resources + operations.” May the entire industry unite to break through challenges and move forward toward new horizons, allowing quality healthcare to transcend mountains and seas, reaching every life!
Liu Hao, CTO of Tianmu Technology
In 2025, we focused on AI protein design, using the AIACCLBIO® large model as our core, linked with an automated experimental platform, continuously breaking through the bottlenecks of molecular design accuracy and conversion efficiency, gradually transforming technological advantages into industrial productivity. Looking to 2026, may we walk alongside industry colleagues, using technological innovation as our sail and practical action as our oar to drive AI protein design technology across the divide between R&D and industry, injecting new momentum into biopharmaceuticals, functional foods, and biomaterials. Let us not disappoint the industry’s expectations or the mission of the times.
Tang Yongzhai, Chairman of Tekang Pharmaceuticals
As the new year begins, we reflect on 2025, where the special medical food industry saw breakthroughs driven by policies and clinical needs, surpassing a domestic production rate of 87%. Innovations in liquid dosage forms and precise nutritional interventions became key to breaking through. Tekang Pharmaceuticals has focused on nutrition formulas for specific diseases, leveraging “local research and development + quality control throughout the chain” to transition nutrition treatment for chronic diseases like cancer, kidney disease, and Alzheimer’s from hospitals to homes, allowing scientific nutrition to benefit millions of patients. Looking to 2026, the industry will accelerate towards a new stage of “precision + intelligence.” We hope to work with academia, industry, and healthcare to unlock health secrets through technology, providing customized nutrition and AI-powered health management, breaking through boundaries in special medical food dosage forms and scenarios, and building an ecological loop of “products + services + data.” May the light of the new year illuminate every path of innovation, making nutritional therapy an indispensable cornerstone of health in China!
Chen Feng, CEO of Boliang Capital
At the beginning of the new year, Boliang Capital, along with all its colleagues, extends sincere blessings to our partners in the healthcare sector! May the new year see a surge of innovation in the industry, fostering win-win cooperation, and embarking on a new journey of high-quality development together. Looking forward to 2026, global pharmaceutical innovation and cross-border cooperation will accelerate. Leveraging the industrial foundation of Kelinlikang and my over 20 years of experience in multinational pharmaceutical management and BD, we will continue to delve into biopharmaceuticals and high-end equipment, connecting with over 10,000 pharmaceutical companies, biotech firms, and investment networks globally, providing comprehensive support for enterprises in licensing, clinical strategies, and financing, facilitating stable international expansion of Chinese innovation and precise localization of global resources. Let us work together with industry peers to propel the co-construction of the healthcare ecosystem and embrace a new chapter of industry integration and breakthroughs!
Wang Wenming, Global Market Director of Haier Bio
Looking to the future, we are at a critical juncture of intelligent and personalized transformations in global biomedicine. AI + automation is reconstructing research laboratory scenarios, and green refrigeration technology is aiding global carbon neutrality—competition in the next decade will unfold at the intersection of technical depth and ecological breadth. Haier Bio’s mission in overseas markets is not just to export Chinese products but to co-create and build with global partners. We aim to be practical builders crossing the “valley of death”: enhancing medical infrastructure in emerging markets and assisting developed markets in upgrading research and medical services intelligently; we also aspire to be dreamers who dare to define the future: actively exploring global brand creation, becoming the top share in key countries like the UK, firmly maintaining original technology, continually leading the industry’s technological development route, and participating in the formulation of international standards for cell storage.
In 2026, let us embrace global innovative resources with a more open posture and climb into uncharted technical territories with more determined steps. The spring breeze has arrived, and everything is renewed. May we, on this most meaningful path of safeguarding life, address current challenges while gazing at the stars to create infinite possibilities. The future is ours!
Dr. Hao Yuyou, Founder and Chairman of Mansen Biotechnology
The New Year brings a fresh chapter. Mansen Biotechnology, with its dedication to craftsmanship, witnesses every leap in China’s biopharmaceutical innovation. May the flame of innovation in China’s biopharmaceutical industry burn brighter through the tempering of cycles, ultimately creating a sweeping force. In the future, Mansen will continue to focus on high-quality raw cells as the foundation for innovation, high-efficiency cryopreservation solutions as a safeguard for life, and precise magnetic beads to empower research purification, accelerating result transformation, and breaking through the industry alongside the Chinese biopharmaceutical community.
Hu Meirong, General Manager of Yilian Health
In 2025, we laid the foundation for our “Eight Dimensions Integration” full-chain service in Chengdu Wenjiang Digital Medical Industrial Park, weaving a network covering system solutions, license applications, physician groups, pharmaceutical supply chains, digital marketing for doctors, and cloud clinic joint operations, ensuring that every step in digital healthcare is solid and powerful. In 2026, let us continue to be the “water bearers” of the industry, using the Chengdu Wenjiang industrial park as a hub to strengthen the national service network, allowing more resident enterprises to share the triadic dividends of “policies + resources + operations.” May the entire industry unite to break through challenges and move forward toward new horizons, allowing quality healthcare to transcend mountains and seas, reaching every life!
Liu Hao, CTO of Tianmu Technology
In 2025, we focused on AI protein design, using the AIACCLBIO® large model as our core, linked with an automated experimental platform, continuously breaking through the bottlenecks of molecular design accuracy and conversion efficiency, gradually transforming technological advantages into industrial productivity. Looking to 2026, may we walk alongside industry colleagues, using technological innovation as our sail and practical action as our oar to drive AI protein design technology across the divide between R&D and industry, injecting new momentum into biopharmaceuticals, functional foods, and biomaterials. Let us not disappoint the industry’s expectations or the mission of the times.
Tang Yongzhai, Chairman of Tekang Pharmaceuticals
As the new year begins, we reflect on 2025, where the special medical food industry saw breakthroughs driven by policies and clinical needs, surpassing a domestic production rate of 87%. Innovations in liquid dosage forms and precise nutritional interventions became key to breaking through. Tekang Pharmaceuticals has focused on nutrition formulas for specific diseases, leveraging “local research and development + quality control throughout the chain” to transition nutrition treatment for chronic diseases like cancer, kidney disease, and Alzheimer’s from hospitals to homes, allowing scientific nutrition to benefit millions of patients. Looking to 2026, the industry will accelerate towards a new stage of “precision + intelligence.” We hope to work with academia, industry, and healthcare to unlock health secrets through technology, providing customized nutrition and AI-powered health management, breaking through boundaries in special medical food dosage forms and scenarios, and building an ecological loop of “products + services + data.” May the light of the new year illuminate every path of innovation, making nutritional therapy an indispensable cornerstone of health in China!
Chen Feng, CEO of Boliang Capital
At the beginning of the new year, Boliang Capital, along with all its colleagues, extends sincere blessings to our partners in the healthcare sector! May the new year see a surge of innovation in the industry, fostering win-win cooperation, and embarking on a new journey of high-quality development together. Looking forward to 2026, global pharmaceutical innovation and cross-border cooperation will accelerate. Leveraging the industrial foundation of Kelinlikang and my over 20 years of experience in multinational pharmaceutical management and BD, we will continue to delve into biopharmaceuticals and high-end equipment, connecting with over 10,000 pharmaceutical companies, biotech firms, and investment networks globally, providing comprehensive support for enterprises in licensing, clinical strategies, and financing, facilitating stable international expansion of Chinese innovation and precise localization of global resources. Let us work together with industry peers to propel the co-construction of the healthcare ecosystem and embrace a new chapter of industry integration and breakthroughs!
Wang Wenming, Global Market Director of Haier Bio
Looking to the future, we are at a critical juncture of intelligent and personalized transformations in global biomedicine. AI + automation is reconstructing research laboratory scenarios, and green refrigeration technology is aiding global carbon neutrality—competition in the next decade will unfold at the intersection of technical depth and ecological breadth. Haier Bio’s mission in overseas markets is not just to export Chinese products but to co-create and build with global partners. We aim to be practical builders crossing the “valley of death”: enhancing medical infrastructure in emerging markets and assisting developed markets in upgrading research and medical services intelligently; we also aspire to be dreamers who dare to define the future: actively exploring global brand creation, becoming the top share in key countries like the UK, firmly maintaining original technology, continually leading the industry’s technological development route, and participating in the formulation of international standards for cell storage.
In 2026, let us embrace global innovative resources with a more open posture and climb into uncharted technical territories with more determined steps. The spring breeze has arrived, and everything is renewed. May we, on this most meaningful path of safeguarding life, address current challenges while gazing at the stars to create infinite possibilities. The future is ours!
Original article by NenPower, If reposted, please credit the source: https://nenpower.com/blog/chinese-innovative-companies-unite-to-celebrate-the-new-year-with-inspiring-messages/
